IE42955B1 - Method of preparing stable sterile crystalline cephalosporins for parenteral administration - Google Patents
Method of preparing stable sterile crystalline cephalosporins for parenteral administrationInfo
- Publication number
- IE42955B1 IE42955B1 IE316/76A IE31676A IE42955B1 IE 42955 B1 IE42955 B1 IE 42955B1 IE 316/76 A IE316/76 A IE 316/76A IE 31676 A IE31676 A IE 31676A IE 42955 B1 IE42955 B1 IE 42955B1
- Authority
- IE
- Ireland
- Prior art keywords
- cephalosporin
- preparation
- temperature
- sodium
- hours
- Prior art date
Links
- 229930186147 Cephalosporin Natural products 0.000 title claims abstract description 63
- 229940124587 cephalosporin Drugs 0.000 title claims abstract description 63
- 150000001780 cephalosporins Chemical class 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000007911 parenteral administration Methods 0.000 title claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000006911 nucleation Effects 0.000 claims abstract description 14
- 238000010899 nucleation Methods 0.000 claims abstract description 14
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 40
- 239000013078 crystal Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 23
- 239000003708 ampul Substances 0.000 claims description 16
- 229960003866 cefaloridine Drugs 0.000 claims description 15
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 15
- 229960000603 cefalotin Drugs 0.000 claims description 14
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims description 14
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 claims description 13
- 229960003408 cefazolin sodium Drugs 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940083542 sodium Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 2
- 229910052753 mercury Inorganic materials 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 abstract description 17
- 239000000463 material Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/567,224 US4029655A (en) | 1975-04-11 | 1975-04-11 | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE42955L IE42955L (en) | 1976-10-11 |
| IE42955B1 true IE42955B1 (en) | 1980-11-19 |
Family
ID=24266257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE316/76A IE42955B1 (en) | 1975-04-11 | 1976-02-18 | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US4029655A (enExample) |
| JP (1) | JPS51123813A (enExample) |
| BE (1) | BE840280A (enExample) |
| CA (1) | CA1068680A (enExample) |
| DE (1) | DE2614668C2 (enExample) |
| ES (1) | ES446906A1 (enExample) |
| FR (1) | FR2306993A1 (enExample) |
| GB (1) | GB1537874A (enExample) |
| IE (1) | IE42955B1 (enExample) |
| IL (1) | IL49073A (enExample) |
| NL (1) | NL7603659A (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996355A (en) * | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
| IL53427A0 (en) * | 1976-11-24 | 1978-01-31 | Lilly Co Eli | Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration |
| US4115644A (en) * | 1977-09-19 | 1978-09-19 | Eli Lilly And Company | Process for preparing pure cefamandole from alkali metal and ammonium salts thereof |
| US4132848A (en) * | 1977-11-03 | 1979-01-02 | Eli Lilly And Company | Method of preparing a rapidly dissolving powder of crystalline cephalothin sodium for parenteral administration |
| FR2421905A1 (fr) * | 1977-11-24 | 1979-11-02 | Lilly Co Eli | Preparation d'une poudre de cephalothine-sodiu m stable, pour administration parenterale |
| JPS54147917A (en) * | 1978-05-08 | 1979-11-19 | Sumitomo Chem Co Ltd | Ferrze-drying method |
| YU44680B (en) * | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| JPS60120886A (ja) * | 1983-12-02 | 1985-06-28 | Takeda Chem Ind Ltd | セフェムカルボン酸のナトリウム塩の結晶 |
| JPH06786B2 (ja) * | 1984-02-22 | 1994-01-05 | 塩野義製薬株式会社 | セフアロチンナトリウムの結晶性凍結乾燥製剤の製造法 |
| US4910301A (en) * | 1985-08-05 | 1990-03-20 | Bristol-Myers Company | Cefepime cephalosporin salts |
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| US4714760A (en) * | 1985-08-20 | 1987-12-22 | Bristol-Myers Company | Cephalosporin intermediates |
| US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| TW264475B (enExample) * | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| US6111098A (en) * | 1994-05-02 | 2000-08-29 | Shionogi & Co., Ltd. | Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same |
| DE602005002742T2 (de) * | 2004-04-22 | 2008-01-24 | Pfizer Products Inc., Groton | Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz |
| CN101759708B (zh) * | 2008-12-23 | 2012-07-04 | 深圳信立泰药业股份有限公司 | 头孢地嗪钠晶型及其制备方法和含有该晶型的药物组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3085884A (en) * | 1958-07-28 | 1963-04-16 | Liquefreeze Company Inc | Method of freezing and shipping foodstuffs |
| GB1234802A (en) * | 1968-04-19 | 1971-06-09 | British American Tobacco Co | Improvements relating to the packing of liquids |
| US3725003A (en) * | 1969-11-04 | 1973-04-03 | Moore Perk Corp | Method of sterile packaging |
-
1975
- 1975-04-11 US US05/567,224 patent/US4029655A/en not_active Expired - Lifetime
-
1976
- 1976-02-18 IE IE316/76A patent/IE42955B1/en unknown
- 1976-02-19 IL IL49073A patent/IL49073A/xx unknown
- 1976-02-20 CA CA246,175A patent/CA1068680A/en not_active Expired
- 1976-03-31 FR FR7609360A patent/FR2306993A1/fr active Granted
- 1976-04-01 JP JP51036674A patent/JPS51123813A/ja active Granted
- 1976-04-01 BE BE1007297A patent/BE840280A/xx not_active IP Right Cessation
- 1976-04-05 DE DE2614668A patent/DE2614668C2/de not_active Expired
- 1976-04-07 NL NL7603659A patent/NL7603659A/xx not_active Application Discontinuation
- 1976-04-07 GB GB14019/76A patent/GB1537874A/en not_active Expired
- 1976-04-10 ES ES446906A patent/ES446906A1/es not_active Expired
-
1977
- 1977-02-09 US US05/767,234 patent/US4104391A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA1068680A (en) | 1979-12-25 |
| IL49073A (en) | 1979-03-12 |
| BE840280A (fr) | 1976-10-01 |
| DE2614668C2 (de) | 1986-10-30 |
| DE2614668A1 (de) | 1976-10-21 |
| US4104391A (en) | 1978-08-01 |
| IL49073A0 (en) | 1976-04-30 |
| JPS6143356B2 (enExample) | 1986-09-26 |
| NL7603659A (nl) | 1976-10-13 |
| JPS51123813A (en) | 1976-10-28 |
| FR2306993B1 (enExample) | 1978-11-17 |
| GB1537874A (en) | 1979-01-04 |
| IE42955L (en) | 1976-10-11 |
| FR2306993A1 (fr) | 1976-11-05 |
| US4029655A (en) | 1977-06-14 |
| ES446906A1 (es) | 1977-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE42955B1 (en) | Method of preparing stable sterile crystalline cephalosporins for parenteral administration | |
| US4146971A (en) | Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration | |
| US20070196364A1 (en) | Pharmaceutical Formulation and Process | |
| US4959215A (en) | Ifosfamide-mesna lyophilizate and process for its preparation | |
| US4002748A (en) | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration | |
| KR900003491B1 (ko) | 이포스파미드 동결건조물 및 이의 제조방법 | |
| US4132848A (en) | Method of preparing a rapidly dissolving powder of crystalline cephalothin sodium for parenteral administration | |
| US10149857B2 (en) | Lyophilized cyclophosphamide composition and methods of preparation thereof | |
| JPS6019759B2 (ja) | 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号 | |
| GB1589317A (en) | Freeze drying cephalothin sodium | |
| CA1079720A (en) | Method of preparing a rapidly dissolving powder of crystalline cephalothin sodium for parenteral administration | |
| CN111419804A (zh) | 一种注射用血管生成抑肽冻干制剂及其冻干方法 | |
| US7323572B2 (en) | Process for controlling the hydrate mix of a compound | |
| JPS6168412A (ja) | 医薬品の凍結乾燥方法 | |
| JP2988631B2 (ja) | ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法 | |
| EP1534721B1 (en) | Process for controlling the hydrate mix of the disodium salt of fosfluconazole | |
| IE45995B1 (en) | Improvements in or relating to freeze drying cephalothin sodium | |
| FI68055B (fi) | Foerfarande foer framstaellning av ett snabbloesligt pulver avristallint cefalotinnatrium | |
| HK40087588A (zh) | 含有具有邻苯二酚基的头孢菌素类的冷冻干燥制剂及其制造方法 | |
| DK142420B (da) | Fremgangsmåde til fremstilling af i det væsentlige krystallinsk natriumcephalotin. | |
| GB2167302A (en) | Stable lyophilized antibacterial preparations | |
| Sundaramurthi | Solute crystallization in the frozen and freeze-dried systems: Inhibition of crystallization to enhance pharmaceutical stability | |
| SE416733B (sv) | Forfarande for framstellning av i huvudsak kristallint cefalotinnatrium | |
| WO2022025091A1 (ja) | カテコール基を有するセファロスポリン類を含有する凍結乾燥製剤およびその製造方法 | |
| IE45353B1 (en) | A procress for preparing solid sodium amoxycillin |